163 related articles for article (PubMed ID: 38177194)
1. Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study.
Asanad K; Horns JJ; Driggs N; Samplaski MK; Hotaling JM
Int J Impot Res; 2024 Jan; ():. PubMed ID: 38177194
[TBL] [Abstract][Full Text] [Related]
2. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
3. Exogenous Testosterone Replacement Therapy Is Associated with Increased Risk for Vascular Graft Infections Among Hypogonadal Men.
Longwolf KJ; Johnson CE; Horns JJ; Hotaling JM; Brooke BS
Ann Vasc Surg; 2023 Nov; 97():113-120. PubMed ID: 37453467
[TBL] [Abstract][Full Text] [Related]
4. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
6. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
Gray H; Seltzer J; Talbert RL
Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
[TBL] [Abstract][Full Text] [Related]
8. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
9. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
Yassin A; Salman M; Talib RA; Yassin DJ
Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
[TBL] [Abstract][Full Text] [Related]
10. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
11. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
[TBL] [Abstract][Full Text] [Related]
12. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Hypogonadism on Surgical Outcomes Following Primary Urethroplasty: Analysis of a Large Multi-institutional Database.
Gabrielson AT; Galansky L; Shneyderman M; Cohen AJ
Urology; 2024 Mar; 185():116-123. PubMed ID: 38190864
[TBL] [Abstract][Full Text] [Related]
16. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Study Using a Web Survey to Identify Characteristics That Influence Hypogonadal Men to Initiate Testosterone Replacement Therapy.
Rosen RC; Seftel AD; Ruff DD; Muram D
Am J Mens Health; 2018 May; 12(3):567-574. PubMed ID: 26819183
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
20. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]